Spyre Therapeutics (SYRE) Cash & Equivalents: 2015-2025
Historic Cash & Equivalents for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $64.9 million.
- Spyre Therapeutics' Cash & Equivalents fell 9.34% to $64.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year decrease of 9.34%. This contributed to the annual value of $89.4 million for FY2024, which is 52.66% down from last year.
- Latest data reveals that Spyre Therapeutics reported Cash & Equivalents of $64.9 million as of Q3 2025, which was down 20.53% from $81.7 million recorded in Q2 2025.
- Spyre Therapeutics' Cash & Equivalents' 5-year high stood at $235.4 million during Q2 2023, with a 5-year trough of $14.6 million in Q1 2022.
- In the last 3 years, Spyre Therapeutics' Cash & Equivalents had a median value of $81.7 million in 2025 and averaged $107.2 million.
- In the last 5 years, Spyre Therapeutics' Cash & Equivalents tumbled by 83.19% in 2021 and then soared by 545.67% in 2024.
- Over the past 5 years, Spyre Therapeutics' Cash & Equivalents (Quarterly) stood at $15.1 million in 2021, then skyrocketed by 130.24% to $34.9 million in 2022, then skyrocketed by 441.82% to $188.9 million in 2023, then plummeted by 52.66% to $89.4 million in 2024, then decreased by 9.34% to $64.9 million in 2025.
- Its last three reported values are $64.9 million in Q3 2025, $81.7 million for Q2 2025, and $48.5 million during Q1 2025.